DFDA

Liver Transplantation

Treatment for Hepatoblastoma

Effectiveness
80%
Safety Score
25%
Clinical Trials
5
Participants
8K

Comparative Safety Scale(Higher is safer)

Cyanideโ˜ ๏ธ
Meth๐Ÿ’€
Cigarettes๐Ÿšฌ
Chemoโ˜ข๏ธ
Alcohol๐Ÿบ
Morphine๐Ÿ’Š
Antibiotics๐Ÿ’‰
Tylenol๐Ÿ’Š
Exercise๐Ÿƒ
Water๐Ÿ’ง
25
DangerousModerateSafe
Treatment Details
Time to Effect
immediate (tumor removal), long recovery
Treatment Duration
Acute event, lifelong immunosuppression
Evidence Quality
HIGH
Confidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$30,000
Monitoring:$30,000
Side Effect Mgmt:$20,000
Total Annual:$580,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
MODERATE
ICER
$110,000/QALY
QALYs Gained
20
Outcome-Based Costs
Cost per Responder
$725,000
Cost per Remission
$773,333.33
Liver Transplantation Outcomes

for Hepatoblastoma

Efficacy Outcomes
Overall Effectiveness
+80%
Response Rate
+80%
Remission Rate
+75%
Common Side Effects
Organ rejection
+20%
Infection
+50%
Biliary complications
+15%
Kidney dysfunction
+30%
Post-transplant lymphoproliferative disorder (PTLD)
+5%

WARNING: LIMITED TRIALS AVAILABLE

You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!

Active Clinical Trials
No active trials currently recruiting for this treatment

No active trials found in ClinicalTrials.gov

Completed Clinical Trials
2 completed trials for Liver Transplantation in Hepatoblastoma

Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer

NCT00980460COMPLETEDPHASE3
View Study
236 participants
INTERVENTIONAL
Birmingham, United States +208 more
Started: Sep 15, 2009

Peripheral Stem Cell Transplantation Plus Chemotherapy in Treating Patients With Malignant Solid Tumors

NCT00007813COMPLETEDPHASE1
View Study
21 participants
INTERVENTIONAL
Baltimore, United States
Started: May 31, 1997